3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Ovarian Neoplasms
9
Fallopian Tube Neoplasms
8
Neoplasms
6
Prostatic Neoplasms
5
Carcinoma, Ovarian Epithelial
5
Recurrence
3
Pancreatic Neoplasms
3
Breast Neoplasms
3
Urinary Bladder Neoplasms
2
Metastatic Castration Resistant Prostate Cancer
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Solid Tumor
1
Sarcoma
1
Primary Myelofibrosis
1
Pathologic Complete Response
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Interventions
pembrolizumab
40
Gemcitabine
37
Cisplatin
28
Carboplatin
17
enfortumab vedotin
15
Nivolumab
15
Mitomycin
14
atezolizumab
13
avelumab
12
Docetaxel
10
vinflunine
9
5-aminolevulinic acid hexyl ester
9
apaziquone
8
Paclitaxel
8
BCG Vaccine
7
durvalumab
6
Fluorouracil
6
Cystectomy
6
sacituzumab govitecan
4
Surgical Procedures, Operative
4
Drug Therapy
4
vofatamab
3
valrubicin
3
tisotumab vedotin
3
erdafitinib
3
cemiplimab
3
belinostat
3
Therapeutic Uses
3
Ramucirumab
3
Cystoscopy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Urinary Bladder Neoplasms
×
rucaparib
×
Clear all
NCT04171700
2023-10-02
LODESTAR
pharmaand GmbH
Phase 2
Terminated
83 enrolled
16 charts
NCT03397394
2023-06-09
ATLAS
pharmaand GmbH
Phase 2
Terminated
97 enrolled
12 charts